AMP-017

AMP-017 is a generic metered-dose inhaler (MDI) drug candidate being developed by Amphastar France Pharmaceuticals, a subsidiary of Amphastar Pharmaceuticals. The product is part of Amphastar's portfolio of complex generic inhalation therapies, which utilize specialized aerosol delivery technology. As of early 2026, AMP-017 is in the IND-enabling phase of development. While the specific active pharmaceutical ingredient (API) has not been publicly disclosed by the sponsor, the candidate is intended to be a generic version of a reference branded MDI, likely targeting respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). The development process focuses on achieving bioequivalence to the reference product through rigorous characterization of the drug-device combination.